Abstract
<p class="a">Pulmonary non-Hodgkin’s lymphoma is a very rare tumor, which comprises only 0.5 % of all malignancies of lungs. Recommended treatment options include complete surgical excision, surgery followed by radiotherapy or chemotherapy alone but, the optimal therapy remains unclear. The article presents the results of treatment of the patient with primary pulmonary lymphoma, who achieved a partial response after four courses of R-CHOP chemotherapy.</p>
Highlights
Pulmonary non-Hodgkins lymphoma (NHL) is a very rare tumor, which comprises only 0.5 % of all malignancies of lungs, it is a rare entity and accounts less than 1 % of all lymphomas [3]
We describe here the case of pulmonary Mucose-associated lymphoid tissue (MALT) lymphoma which had obtained partial response after extended 4 cycles of rituximab treatment [5]
Primary non-Hodgkins lymphoma of the lung is of a rare entity and the prognosis of bronchial-associated lymphoid tissue (BALT) lymphomas is favorable with 5-yr survival rates of over 85 % and median survival of over 10 yrs in the largest reported series, clinical features, prognostic factors, and patient management was not clearly defined
Summary
Pulmonary non-Hodgkins lymphoma (NHL) is a very rare tumor, which comprises only 0.5 % of all malignancies of lungs, it is a rare entity and accounts less than 1 % of all lymphomas [3]. Lymphoma of lungs originates from bronchial-associated lymphoid tissue (BALT), which is histologically different from true intrapulmonary lymph nodes. Mucose-associated lymphoid tissue (MALT) lymphomas most commonly arise from gastrointestinal tract, they have been described in a wide variety of extranodal sites of the body, including salivary glands, orbit and ocular adnexae, lung, skin, thyroid gland, breast, liver, kidney, bladder and prostate. It has been showed that chronic antigenic stimulation, smoking and some autoimmune diseases could play a role as a trigger for the pulmonary MALT lymphomas[4]. An alternative to cytotoxic chemotherapy is the use of rituximab, because lymphadenopathy or other lesions typical for lymphoma (eg, spleen) that could touch up on the idea of lymphoproliferative nature of the lesion
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
